Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.
BMC Psychiatry March 17, 2026 Bernhard T. Baune, Kevin Rosemann, Dimitri Hefter et al. 2 citations
In real-world clinical settings, intranasal esketamine shows effectiveness for treatment-resistant depression, with response varying based on patient characteristics. The text describes factors associated with treatment response but does not specify which factors or provide concrete numbers.